Early improvement of psychotic symptoms with lithium monotherapy as a predictor of later response in mania

Journal of Psychiatric Research

Volumn 46, Issue 12, 2012, Pages 1564-1568

  de Sousa, Rafael T ^a   Busnello, Joao V ^b   Forlenza, Orestes V ^a   Zanetti, Marcus V ^a   Soeiro de Souza, Marcio G ^a   van de Bilt, Martinus T ^a   Moreno, Ricardo A ^a   Zarate, Carlos A ^c   Gattaz, Wagner F ^a   Machado Vieira, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CHICAGO   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bipolar disorder; Early improvement; Lithium; Mania; Monotherapy; Psychosis

Indexed keywords

LITHIUM;

ACUTE DISEASE; ADULT; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; SUBSTANCE ABUSE; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE;

EID: 84868119057     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.08.011     Document Type: Article

References (25)

1. Bora E., Yücel M., Pantelis C. Neurocognitive markers of psychosis in bipolar disorder: a meta-analytic study. Journal of Affective Disorders 2010, 127:1-9.
2. Bowden C.L., Grunze H., Mullen J., Brecher M., Paulsson B., Jones M., et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Journal of Clinical Psychiatry 2005, 66:111-121.
3. Coryell W., Leon A.C., Turvey C., Akiskal H.S., Mueller T., Endicott J. The significance of psychotic features in manic episodes: a report from the NIMH collaborative study. Journal of Affective Disorders 2001, 67:79-88.
4. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV TR axis I disorders, research version, patient edition (SCID-I/P) 2001, New York State Psychiatric Institute, Biometrics Research, New York.
5. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2009, 23:346-388. Consensus Group of the British Association for Psychopharmacology.
6. Grandjean E.M., Aubry J.M. Lithium: updated human knowledge using an evidence-based approach: part I: clinical efficacy in bipolar disorder. CNS Drugs 2009, 23:225-240.
7. Houston J.P., Gatz J.L., Degenhardt E.K., Jamal H.H. Symptoms predicting remission after divalproex augmentation with olanzapine in partially nonresponsive patients experiencing mixed bipolar I episode: a post-hoc analysis of a randomized controlled study. BMC Research Notes 2010, 3:276.
8. Keck P.E., McElroy S.L., Havens J.R., Altshuler L.L., Nolen W.A., Frye M.A., et al. Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Comprehensive Psychiatry 2003, 44:263-269.
9. Keck P.E., Orsulak P.J., Cutler A.J., Sanchez R., Torbeyns A., Marcus R.N., et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. Journal of Affective Disorders 2009 Jan, 112:36-49. CN138-135 Study Group.
10. Kemp D.E., Johnson E., Wang W.V., Tohen M., Calabrese J.R. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. Journal of Clinical Psychiatry 2011, 72:1236-1241.
11. Kemp D.E., Ganocy S.J., Brecher M., Carlson B.X., Edwards S., Eudicone J.M., et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. Journal of Affective Disorders 2011, 130:171-179.
12. Ketter T.A., Agid O., Kapur S., Loebel A., Siu C.O., Romano S.J. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. Journal of Psychiatric Research 2010, 44:8-14.
13. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Sniadecki J.L., et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 2008, 102:230-240.
14. Machado-Vieira R., Soares J.C., Lara D.R., Luckenbaugh D.A., Busnello J.V., Marca G., et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. Journal of Clinical Psychiatry 2008, 69:1237-1245.
15. Malhi G.S., Adams D., Lampe L., Paton M., O'Connor N., Newton L.A., et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatrica Scandinavica. Supplementum 2009, 439:27-46. Northern Sydney Central Coast mental health drug & alcohol; NSW Health Clinical Redesign Program; CADE Clinic, University of Sydney.
16. McElroy S.L., Keck P.E., Strakowski S.M. Mania, psychosis, and antipsychotics. Journal of Clinical Psychiatry 1996, 57(Suppl. 3):14-26.
17. Pope H.G., Lipinski J.F. Diagnosis in schizophrenia and manic-depressive illness: a reassessment of the specificity of 'schizophrenic' symptoms in the light of current research. Archives of General Psychiatry 1978, 35:811-828.
18. Prien R.F., Caffey E.M., Klett C.J. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Archives of General Psychiatry 1972, 26:146-153.
19. Small J.G., Klapper M.H., Marhenke J.D., Milstein V., Woodham G.C., Kellams J.J. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacological Bulletin 1995, 31:265-272.
20. Szegedi A., Jansen W.T., van Willigenburg A.P., van der Meulen E., Stassen H.H., Thase M.E. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. Journal of Clinical Psychiatry 2009, 70:344-353.
21. Swann A.C., Bowden C.L., Calabrese J.R., Dilsaver S.C., Morris D.D. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002 Apr, 26:530-536.
22. Swann A.C., Daniel D.G., Kochan L.D., Wozniak P.J., Calabrese J.R. Psychosis in mania: specificity of its role in severity and treatment response. Journal of Clinical Psychiatry 2004, 65:825-829.
23. Tohen M., Waternaux C.M., Tsuang M.T. Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Archives of General Psychiatry 1990, 47:1106-1111.
24. Yatham L.N., Kennedy S.H., Schaffer A., Parikh S.V., Beaulieu S., O'Donovan C., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 2009, 11:225-255.
25. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 1978, 133:429-435.